Non-Cystic Fibrosis Bronchiectasis Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight

Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others.
According to DelveInsight's analysis, the global Non-Cystic Fibrosis Bronchiectasis pipeline features over 16 leading companies actively advancing more than 17 therapeutic candidates, with ongoing evaluations of their clinical trials, mechanisms of action, routes of administration, and developmental progress.

DelveInsight's "Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025" report delivers a thorough overview of the current clinical landscape and future opportunities within the Non-Cystic Fibrosis Bronchiectasis market. The report offers an extensive commercial and clinical evaluation of pipeline therapies, spanning from preclinical stages to approved products. It includes detailed profiles of each drug candidate, covering their mechanisms of action, clinical trial progress, regulatory milestones, and product development updates such as technological advancements, partnerships, mergers and acquisitions, funding activities, designations, and other relevant attributes.

Request for Sample Report @ [https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report:

* NCFB Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years.
* Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment.
* Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years.
* In August 2025, Insmed Incorporated revealed that the FDA had approved BRINSUPRI (brensocatib 10 mg and 25 mg tablets), a first-in-class, once-daily oral therapy for treating NCFB in adults and children aged 12 and above.
* In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting.
* On 17 August 2025, Verona Pharma plc announced a study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
* In June 2025, Insmed Incorporated announced plans to launch an underwritten public offering of $650 million in common stock. The company also expects to provide underwriters with a 30-day option to purchase up to an additional $97.5 million in shares. All shares in the offering will be issued and sold by Insmed. The completion, size, and terms of the offering remain subject to market conditions and other factors, and there is no guarantee that it will be finalized.
* In May 2025, Insmed presented 11 new abstracts at the American Thoracic Society (ATS) 2025 International Conference, including three prespecified subgroup analyses from the Phase III ASPEN trial evaluating brensocatib in NCFB.
* In February 2025, Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brensocatib for patients with non-cystic fibrosis bronchiectasis.
* In July 2024, Armata Pharmaceuticals stated that it had completed enrollment in its Tailwind Phase 2 clinical trial of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection.
* In May 2024, Insmed Incorporated reported encouraging topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate brensocatib's effectiveness, safety, and tolerability in patients with non-cystic fibrosis bronchiectasis. The study accomplished its primary aim, with both brensocatib dose strengths showing statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) compared to placebo. The study also met several of its predetermined secondary goals with statistical significance.
* In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY.
* In December 2022, Haisco Pharmaceutical Group Co., Ltd. has commenced a trial titled "Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study." This study aims to evaluate the effectiveness and safety of HSK31858 in individuals diagnosed with Non-cystic Fibrosis Bronchiectasis.
* In April 2022, The FDA awarded breakthrough therapy designation to colistimethate sodium powder intended for nebulization solution to alleviate pulmonary exacerbations in adults afflicted with Non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa. The basis for the FDA's breakthrough therapy designation was supported by findings from the phase III PROMIS-I study, showcasing that CMS I-neb notably decreased annual rates of pulmonary exacerbations compared to a placebo within this patient population.

Non-Cystic Fibrosis Bronchiectasis Overview

Non-Cystic Fibrosis Bronchiectasis (NCFB) is a chronic, progressive respiratory condition characterized by permanent dilation of the airways, leading to persistent cough, excessive mucus production, and recurrent lung infections. Unlike cystic fibrosis-related bronchiectasis, NCFB arises from various underlying causes such as severe respiratory infections, immune deficiencies, allergic reactions, and genetic disorders. The disease is driven by an ongoing cycle of inflammation and infection, which gradually worsens lung function and quality of life. Diagnosis typically involves CT imaging, sputum analysis, and lung function tests, while treatment focuses on airway clearance therapies, antibiotics, bronchodilators, and emerging targeted approaches to control inflammation and prevent exacerbations.

Get a Free Sample PDF Report to know more about the phases of drugs in development, ROA and MOA , click here @ [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:

* NP339: NovaBiotics Ltd
* Research Programme:NCFB: Synspira Therapeutics
* Research programme: mucolytic agents: Parion Sciences
* CHF 6333: Chiesi Farmaceutic
* CSL787: CSL Behring
* HSK31858: Haisco Pharmaceutical
* S-1226: SolAeroMed Inc.
* Benralizumab: AstraZeneca
* Colistimethate sodium: Zambon SpA
* BI 1291583: Boehringer Ingelheim
* AP-PA02: Armata Pharmaceuticals
* ARINA-1: Renovion

Non-Cystic Fibrosis Bronchiectasis Route of Administration

Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Non-Cystic Fibrosis Bronchiectasis Molecule Type

Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as

* Monoclonal antibody
* Small molecule
* Peptide

Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment

* Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type
* Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type
* Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration
* Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration
* Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type
* Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type

DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 17+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies @ [https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:

Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are - Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others.

Emerging Therapies for Non-Cystic Fibrosis Bronchiectasis

* Brensocatib - Insmed Incorporated

Brensocatib (INS1007/AZD7986) is an oral, reversible small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1). DPP1 activates neutrophil serine proteases (NSPs), including neutrophil elastase, during neutrophil development in the bone marrow. By blocking DPP1, Brensocatib aims to reduce neutrophil-driven inflammation that contributes to bronchiectasis. Insmed licensed the therapy from AstraZeneca in 2016, and it is currently under evaluation in Phase III clinical trials for Non-Cystic Fibrosis Bronchiectasis.

* HSK31858 - Haisco Pharmaceutical Group Co., Ltd.

HSK31858 is a highly selective, potent, orally administered DPP1 inhibitor developed by Haisco Pharmaceutical. By preventing DPP1-mediated activation of neutrophils and related NSP enzymes, the therapy seeks to limit excessive inflammatory responses in the lower respiratory tract. It is being investigated for conditions such as bronchiectasis and acute lung injury/ARDS. Phase I studies in Australia and China have been completed, and Phase II trials are now underway with positive progress.

* CSL787 - CSL Behring

CSL787 is a nebulized human plasma-derived immunoglobulin designed to help prevent recurring respiratory infections and slow the progression of chronic lung diseases, including Non-Cystic Fibrosis Bronchiectasis. The therapy is currently in Phase I clinical development.

Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies - [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers

Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market.

Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers

However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth.

Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight

* Coverage: Global
* Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others
* Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others
* Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
* Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers

Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials - [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Non-Cystic Fibrosis Bronchiectasis Report Introduction

2. Non-Cystic Fibrosis Bronchiectasis Executive Summary

3. Non-Cystic Fibrosis Bronchiectasis Overview

4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment

5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics

6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III)

7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)

8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)

9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products

10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment

11. Non-Cystic Fibrosis Bronchiectasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Cystic Fibrosis Bronchiectasis Key Companies

14. Non-Cystic Fibrosis Bronchiectasis Key Products

15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs

16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers

17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion

18. Non-Cystic Fibrosis Bronchiectasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-competitive-landscape-2025-clinical-trial-analysis-therapies-fda-approvals-future-outlook-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.